MF59
MF59 is an adjuvant which is used in drug production as an absorption enhancer to increase the effect - e.g. B. in vaccines - is used. It was developed in the 1990s by the pharmaceutical company Ciba-Geigy , which is now part of the Novartis Group . The abbreviation MF is derived from “microfluidization”. MF59 is an oil-in-water emulsion , one dose contains 9.75 mg squalene , 1.175 mg surface-active polysorbate 80 (Tween 80) and 1.175 mg sorbitan trioleate (Span 85), sodium citrate and citric acid . After injection, more and more immunocompetent cells migrate to the injection site. These then take up the antigens more efficiently and are then increasingly presented in the lymph nodes . As a result, more T and B cells are finally activated and the production of corresponding antibodies is increased.
MF59 is a stronger adjuvant than aluminum salt-containing adjuvants because it stimulates both antibody production and a T-cell mediated immune response.
Currently, MF59 is used in flu vaccines such as B. Fluad used. With MF59, patients are better protected against newly formed variants of the influenza viruses.
Individual evidence
- ↑ Novartis MF59 Adjuvant Fact Sheet ( Memento of the original from October 12, 2013 in the Internet Archive ) Info: The archive link has been inserted automatically and has not yet been checked. Please check the original and archive link according to the instructions and then remove this notice. (PDF; 49 kB)
- ↑ a b c d Adjuvants: Boosters for vaccination. Pharmaceutical newspaper , March 29, 2017, accessed May 22, 2019 .
- ↑ Ralf Wagner and Eberhard Hildt: Composition and mechanisms of action of adjuvants in approved viral vaccines . In: Federal Health Gazette - Health Research - Health Protection . tape 62 , no. 4 , April 1, 2019, p. 462-471 , doi : 10.1007 / s00103-019-02921-1 .
- ↑ Nina Zanina: Vaccine Adjuvants Derived from Marine Organisms . In: Biomolecules . tape 9 , no. 8 , August 3, 2019, doi : 10.3390 / biom9080340 , PMID 31382606 , PMC 6723903 (free full text).
